USO 24114
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy (20230005)
Disease Types: Genitourinary Cancer Research
Eligibility Requirements:
• Histologically, pathologically, and/or cytologically confirmed prostate cancer
• Metastatic disease with ≥ 1 lesion
• Subjects must have prior treatment with at least 1 ARDT & 1 taxane therapy
• Prior treatment with docetaxel in the hormone-sensitive setting is permitted. Prior therapy with ≥2 regimens in the castrate-resistant setting not permitted
• Prior treatment with RLT, radionuclide therapy(Radium-223), PARP inhibitor, or ICIs is permitted.
• Prior radionuclide therapy within 2 months of first dose of study treatment is excluded
• Prior STEAP1-targeted therapy is excluded
For more infomation on this trial CLICK HERE.
Available at: